Agenda

  1.  

    Two sessions will be available for you to view on the conference platform in advance of the conference in the form of 4 separate presentations. Your questions will be addressed during the live Q&As and panel discussions of the conference.

  2. Recent developments in testing and modelling
  3.  

    How to meet the BPR requirement when non-standardized studies need to be developed - a long and uncertain journey

    • When and why do we face this type of situation?
    • What are the options and the strategy for dealing with it?
    • The stages and challenges encountered along the way
    Fabien Rouessay Fabien Rouessay
    Regulatory Project Manager, Biocidal Products, Redebel Regulatory Affairs
  4.  

    BPF: A case study and possible approach to efficacy tests

    Daniela Romano Daniela Romano
    Senior Consultant for Biocidal Products, knoell Germany GmbH
  5.  

    You can submit your questions for both speakers and they will be addressed in the live panel discussion of session 3 on day 1 of the conference.

  6. Sustainable use, innovation and scope issues
  7.  

    Reflections on HCWH report on safer hospital disinfectants on the global market

    • Hospital disinfection - why do we need safer disinfectants?
    • Introduction to SAICM 2.0 project and the WIDES database
    • A survey on the procurement and use of disinfectants within healthcare organisations across the globe
    • Summary of the HCWH report and learning outcomes
    • Future outlook
    Dorota Napierska Dorota Napierska
    Toxic-free Circular Economy Policy Officer, Zero Waste Europe (ZWE)
  8.  

    Probiotic hygiene: alongside or under the BPR?

    • Short explanation of probiotic and synbiotic cleaning/infection control
    • Market evolution in Europe
    • Current grey zones in the BPR with some actual cases
    • Proposed solutions for clearing up the grey zones
    Robin Temmerman Robin Temmerman
    CEO, Chrisal NV, Belgium
  9.  

    You can submit your questions for both speakers and they will be addressed in the live panel discussion of session 6 on day 2 of the conference.

View previous day

/ Next day